Akane Kato

Akane Kato

Auto-generated profile, based on publicly available information

Akane Kato

Department of Respiratory Medicine, Ina Central Hospital, 1313-1, Koshiroukubo, Ina, Nagano, 396-8555, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2018 in Respirology
Verified
Journal Article
Closed access
PDF file
AKAkane Kato
Akane Kato
MYMasanori Yasuo
Masanori Yasuo
YTYayoi Tokoro
Yayoi Tokoro
TKTakashi Kobayashi
Takashi Kobayashi
TITakashi Ichiyama
Takashi Ichiyama
MHMasayuki Hanaoka
Masayuki Hanaoka

1 January 2015 in Haigan
Verified
Journal Article
Closed access
MKMasamichi Komatsu
Masamichi Komatsu
KTKazunari Tateishi
Kazunari Tateishi
AKAkane Kato
Akane Kato
NKNobumitsu Kobayashi
Nobumitsu Kobayashi
MHMasayuki Hanaoka
Masayuki Hanaoka
SYShoji Yomo
Shoji Yomo

7 July 2016 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
AKAkane Kato
Akane Kato
HYHiroshi Yamamoto
Hiroshi Yamamoto
MIMariko Ikeda
Mariko Ikeda
KTKazunari Tateishi
Kazunari Tateishi
AUAtsuhito Ushiki
Atsuhito Ushiki
MHMasayuki Hanaoka
Masayuki Hanaoka
We encountered a middle-aged afebrile immunocompetent woman with a slight cough. Positron emission tomography (PET)/computed tomography (CT) revealed a broad left upper-lobe consolidation without cavity lesions, small nodules, or bronchiectasis showing a positive fluorodeoxyglucose (FDG) uptake with a maximum standardized uptake value (SUVmax) of 26.9. Percutaneous needle lung biopsy specimens showed caseous granulomas without atypical cells and Mycobacterium avium was cultured from left pleural effusion, which developed after the biopsy. The consolidation significantly decreased following combination chemotherapy for approximately 2 years. Clinicians should remember that pulmonary M. avium infection could result in a large consolidation without other typical radiological findings.

26 July 2025 in Respiratory Investigation
Verified
Journal Article
Open access
THTaro Hirabayashi
Taro Hirabayashi
KSKei Sonehara
Kei Sonehara
TTToshiharu Tsutsui
Toshiharu Tsutsui
SNShuhei Nozawa
Shuhei Nozawa
TAToshihiko Agatsuma
Toshihiko Agatsuma
MHMasayuki Hanaoka
Masayuki Hanaoka
First-line combination therapy with anti-programmed cell death ligand 1 antibodies and platinum-based chemotherapy (chemoimmunotherapy) for extensive-disease small cell lung cancer (ED-SCLC) has been shown to be effective in clinical trials and widely used. Since the introduction of chemoimmunotherapy, very few studies have evaluated the treatment details and outcomes for patients with ED-SCLC in clinical settings. We enrolled 181 ED-SCLC patients who received first-line chemotherapy or chemoimmunotherapy at 11 institutions in Japan between August 2019 and June 2023. We retrospectively investigated the characteristics and treatment regimens of patients with ED-SCLC who received first-line treatment. Ninety-six (53.0 %) and 85 (47.0 %) ED-SCLC patients received chemoimmunotherapy and chemotherapy, respectively. The proportions of older patients (≥75 years) and those with interstitial pneumonia were significantly higher in the chemotherapy group than in the chemoimmunotherapy group (age: 56.5 % vs. 28.1 %, p < 0.001; interstitial pneumonia: 41.2 % vs. 9.4 %, p < 0.001, respectively). The median overall survival in chemoimmunotherapy and chemotherapy groups were 15.0 and 9.7 months, respectively. The most common reasons for not selecting chemoimmunotherapy were interstitial pneumonia (34 patients,18.8 %), older age (27 patients, 14.9 %), and poor performance status (24 patients, 13.3 %). Although the efficacy of chemoimmunotherapy for patients with ED-SCLC has been suggested, only about half of the patients with ED-SCLC select chemoimmunotherapy, and there are various challenges in the treatment of ED-SCLC in clinical settings.